Last updated on February 2017

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma


Brief description of study

This first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced adrenocortical carcinoma whose tumor has progressed on standard therapy. Information will also be collected to determine how long ATR-101 stays in the blood, and if any effect on tumor progression is seen. Biomarkers (blood and urine tests) will determine if any effects on production of steroid hormones (cortisol, aldosterone, estrogen and testosterone) are seen.

Clinical Study Identifier: NCT01898715

Find a site near you

Start Over

Moffitt Cancer Center

Tampa, FL United States
  Connect »